Rockefeller Capital Management
ABOS icon

Rockefeller Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Rockefeller Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.08K Hold
3,000
– – ﹤0.01% 4133
2025
Q4 		$6.33K Hold
3,000
– – ﹤0.01% 3987
2025
Q3 		$5.13K Buy
+3,000
New +$4.15K ﹤0.01% 3863

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Rockefeller Capital Management's ABOS Position: Q1 2026 in Review

Rockefeller Capital Management held its Acumen Pharmaceuticals (ABOS) position steady in Q1 2026 at 3,000 shares worth $7.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4133.

Rockefeller Capital Management first reported a position in ABOS in Q3 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Rockefeller Capital Management held 3,000 shares of Acumen Pharmaceuticals worth $7.08K as of Q1 2026.
  • Rockefeller Capital Management left its Acumen Pharmaceuticals share count unchanged in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4133 holding.
  • Rockefeller Capital Management first reported a position in Acumen Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.